Abstract
OPINION article Front. Oncol., 04 September 2020Sec. Hematologic Malignancies Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.01626
Highlights
Michele Malagola 1*, Nicola Polverelli 1, Lisa Gandolfi 1, Tatiana Zollner 1, Simona Bernardi 1,2, Camilla Zanaglio 1,2, Federica Re 1,2, Enrico Morello 1, Alessandro Turra 1, Alessandro Isidori 3 and Domenico Russo 1
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemia and disease [coronavirus disease 2019 (COVID 19)] importantly changed the management of hematological patients [1], in particular those affected by acute leukemias, for whom allogeneic stem cell transplantation is a mainstay toward the cure of the disease [2]
Any efforts for the rapid and correct diagnosis of the hematological disease continued to be made even during the pandemia, but undoubtedly, some changes in the decision algorithms have been considered to avoid infective risk for the patient. This is the case of deferrable treatments, such as those for indolent lymphomas or multiple myeloma in some cases, for which chemotherapy postponement can reduce the risk to be infected by SARS-CoV-2 and the incidence of treatment-related complications, which can put the patient at risk to develop COVID 19
Summary
Michele Malagola 1*, Nicola Polverelli 1, Lisa Gandolfi 1, Tatiana Zollner 1, Simona Bernardi 1,2, Camilla Zanaglio 1,2, Federica Re 1,2, Enrico Morello 1, Alessandro Turra 1, Alessandro Isidori 3 and Domenico Russo 1. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemia and disease [coronavirus disease 2019 (COVID 19)] importantly changed the management of hematological patients [1], in particular those affected by acute leukemias, for whom allogeneic stem cell transplantation (allo-SCT) is a mainstay toward the cure of the disease [2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
